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Abstract
Introduction: A hallmark of Alzheimer’s disease (AD) is the presence of senile plaques composed of aggregated
amyloid b (Ab) peptides. Pathological aging (PA) is a postmortem classification that has been used to describe
brains with plaque pathology similar in extent to AD, minimal cortical tau pathology, and no accompanying history
of cognitive decline in the brain donor prior to death. PA may represent either a prodromal phase of AD, a benign
form of Ab accumulation, or inherent individual resistance to the toxic effects of Ab accumulation. To attempt to
distinguish between these possibilities we have systematically characterized Ab peptides in a postmortem series of
PA, AD and non-demented control (NDC) brains.
Methods: Ab was sequentially extracted with tris buffered saline (TBS), radioimmunoprecipitation buffer (RIPA), 2%
sodium dodecyl sulfate (SDS) and 70% formic acid (FA) from the pre-frontal cortex of 16 AD, eight PA, and six NDC
patients. These extracts were analyzed by 1) a panel of Ab sandwich ELISAs, 2) immunoprecipitation followed by
mass spectrometry (IP/MS) and 3) western blotting. These studies enabled us to asses Ab levels and solubility,
peptide profiles and oligomeric assemblies.
Results: In almost all extracts (TBS, RIPA, 2% SDS and 70% FA) the average levels of Ab1-40, Ab1-42, Ab total, and
Abx-42 were greatest in AD. On average, levels were slightly lower in PA, and there was extensive overlap between
Ab levels in individual PA and AD cases. The profiles of Ab peptides detected using IP/MS techniques also showed
extensive similarity between the PA and AD brain extracts. In select AD brain extracts, we detected more amino-
terminally truncated Ab peptides compared to PA patients, but these peptides represented a minor portion of the
Ab observed. No consistent differences in the Ab assemblies were observed by western blotting in the PA and AD
groups.
Conclusions: We found extensive overlap with only subtle quantitative differences between Ab levels, peptide
profiles, solubility, and SDS-stable oligomeric assemblies in the PA and AD brains. These cross-sectional data
indicate that Ab accumulation in PA and AD is remarkably similar. Such data would be consistent with PA
representing a prodromal stage of AD or a resistance to the toxic effects of Ab.
Introduction
Alzheimer’s disease (AD) is characterized by large num-
bers of extracellular amyloid plaques with dense amyloid
cores that are associated with dystrophic neurites and
neuroinflammatory changes as well as intraneuronal
neurofibrillary tangles. Pathological aging (PA) patients
also have abundant and widespread amyloid plaques;
however, these plaques have typically been described as
diffuse in nature. In PA there are fewer cored plaques
and there is little or no inflammatory reaction, neuritic
pathology or neurofibrillary tangles in the cortex. These
patients are reported to be cognitively normal prior to
death [1-3]. Based on our current understanding of the
progression of AD, PA may represent a prodromal
phase of AD (for example, preclinical stage 1 AD, pla-
que only), a benign form of Ab accumulation, or inher-
ent individual resistance to the toxic effects of Ab
accumulation [3,4].
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Ab is the principle component of amyloid deposits in
the AD brain. It is a secreted peptide produced through
sequential cleavage of the Amyloid-b Protein Precursor
(APP) by b- and g-secretases [5-7]. Ab peptides have a
heterogeneous carboxyl-terminus with the majority
(approximately 40% to 70%) composed of 40 amino
acids Ab1-40, while a minor product (approximately 5%
to 20%) contains a two amino acid extension Ab1-42.
Additional minor Ab peptides are also normally pro-
duced (for example, 1-34, 1-37, 1-38 and 1-39), although
few reports have quantified the levels of these peptides
in the brain [8]. Ab1-42 is more amyloidogenic and has
been implicated as the pathogenic form of Ab [9]. A
recent study also suggested that Ab1-43 could play a
critical role in Ab accumulation [10]. Furthermore, a
variety of truncated and modified Ab peptides have
been described (for example, 1-28, 1-29, 1-45, 2-46, 3-
44, 3-47, 2-42, 4-42, 5-42, 6-42, 7-45, 8-42, 1-
42Met35ox, pE3-42, pE11-42) [11-18]. Of these trun-
cated and modified forms the pyroglutamate modified
forms, AbpE3-42 and AbpE11-42, have been highly
investigated, as key species possibly involved in initial
nucleation or seeding events [19-22].
Once liberated from APP, Ab can self-associate to
form various aggregates. These aggregates include solu-
ble oligomers, protofibrils, and amyloid fibrils [23,24].
Although there is currently debate within the field
regarding which form or forms of Ab aggregates are the
most pathogenic, there is general consensus that the
aggregated forms of Ab are harmful and that Ab1-42 or
possibly Ab1-43 is required for aggregation in the
absence of internal mutations within Ab [25-30].
Because many different forms of Ab exist and accu-
mulate in various higher order assemblies, it is possible
that the relatively poor correlation between cognitive
deficits and plaque load is attributable to either qualita-
tive or quantitative differences between a particular spe-
cies or assembly of Ab. This poor correlation could also
reflect an inherent difference in vulnerability to ‘toxic’
effects of different forms of Ab aggregates. Additionally,
given the growing acceptance of the concept of preclini-
cal AD [4,31,32], where the initial stage is defined by
the presence of Ab deposits in the absence of other
pathologies and no evidence for cognitive impairment,
the poor correlation could be attributable to differences
in time from initial deposition to frank neurodegenera-
tion and clinical deterioration.
As PA represents the most clear cut example of the
dissociation between Ab accumulation and cognitive
impairment, investigation of the type and species of Ab
peptides in PA cohorts could provide novel insights into
the poor correlation between Ab and cognition. Pre-
vious studies investigating differences in Ab1-40 and
Ab1-42 species extracted from PA and AD brains
demonstrated that Ab1-40 levels were as much as
approximately 20-fold higher in AD brains compared to
PA brains whereas Ab1-42 levels were only about 2-fold
higher [33]. A more recent and extensive study using
both ELISAs and western blotting to analyze Ab levels
and oligomeric assemblies failed to detect major differ-
ences in PA and AD [34]. Other more anecdotal studies
comparing oligomeric assemblies in a single PA brain
versus AD brains failed to detect significantly elevated
levels of Ab dimer in the PA brain extracts compared to
AD brain extracts [35].
Although these studies suggest that there may be both
quantitative and qualitative differences in Ab peptides in
PA brains as opposed to AD brains, we felt that a more
extensive investigation with larger cohorts was war-
ranted. Here we report on our analysis of Ab peptides
sequentially extracted from the pre-frontal cortices of 16
AD patients, eight PA patients, and six non-demented
controls (NDC) using a battery of biochemical tests.
Our analysis shows that AD and PA brains are clearly
distinct from controls, but there is extensive overlap
between PA and AD with respect to extractable Ab
levels as measured by ELISA. Using immunoprecipita-
tion mass spectrometry (IP/MS) to profile individual Ab
species in the PA and AD brain extracts we find that
there is also extensive overlap in the profiles of accumu-
lated Ab. However, individual AD brains showed more
extensive heterogeneity with an increase of diversity of
Ab species, particularly amino-terminally truncated Ab
species. Assessment of SDS-stable oligomers by western
blotting also showed no consistent differences between
PA and NDC.
Materials and methods
Selection of PA cases
Frozen pre-frontal cortex (AD = 16, PA = 8, NDC = 7)
was obtained from the Mayo Clinic Brain Bank with
informed consent, in accordance with the Mayo Clinic
institutional review board, using previously described
acquisition and diagnostic analyses [2,36,37]. We ana-
lyzed 16 brains from AD patients (age range = 66 to 99;
average age = 82), eight pathologic aging brains from
subjects (age range = 66 to 90; average age = 80) with-
out clinical evidence of dementia and seven brains with
rare or no AD lesions from elderly individuals without
clinical evidence of a neurological illness (age range =
66 to 87; average age = 76). Table 1 summarizes the
cases studied here.
Brain extraction
Frozen pre-frontal cortex tissue was cryo-pulverized in
liquid nitrogen. Briefly, for ELISA and IP/MS, the cryo-
pulverized tissue was sequentially extracted with Tris-
buffered saline (TBS), radioimmunoprecipitation buffer
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(RIPA), 2% sodium dodecyl sulfate (SDS) and 70% for-
mic acid (FA) containing protease inhibitor cocktail
(Roche, Indianapolis, IN, USA) as described before at a
concentration of 300 mg/mL [38]. For immunoblotting,
samples were either serially extracted in TBS and 2%
SDS or directly extracted with RIPA at a concentration
of 500 mg/mL.
ELISA
TBS, RIPA, 2% SDS and neutralized 70% FA extracted
samples were diluted appropriately and used for sand-
wich ELISAs as described previously [39]. Ab1-40 was
captured with monoclonal antibody (mAb) Ab9 (human
Ab1-16 specific; T.E. Golde) and detected by horserad-
ish peroxidase (HRP)-conjugated mAb 13.1.1 (human
Ab35-40 specific; T.E. Golde); Ab1-42 was captured
with mAb 2.1.3 (human Ab35-42 specific; T.E. Golde)
and detected by HRP-conjugated mAb Ab9; Total Ab
was captured with mAb Ab9 and detected by HRP-con-
jugated mAb 4G8 (Covance, Princeton, NJ, USA); Abx-
42 was captured with mAb 2.1.3 and detected by HRP-
conjugated mAb 4G8.
Immunoprecipitation followed by mass spectrometry (IP/
MS)
Magnetic sheep-anti-mouse IgG beads (Invitrogen,
Grand Island, NY, USA) were incubated with 4.5 μg
antibody (either Ab9 or 4G8 (Covance)) for 30 min-
utes at room temperature with constant shaking. The
beads were then washed and incubated with each
extract, which were diluted appropriately. All sample
incubations were in the presence of 0.1% TritonX-100
(Tx-100) and either 10 pmol Ab1-28 (TBS and RIPA
extracts) or 100 pmol Ab1-28 (2% SDS and 70% FA
extracts) as an internal calibration standard. The sam-
ples were successively exposed to Ab9 and 4G8 coated
beads for 30 minutes each with rotation. Bound beads
were washed sequentially with 0.1% and 0.05% Tx-100
followed by water. Samples were eluted using a mix of
75% acetonitrile, 24.9% water and 0.1% FA. Samples
were mixed in equal volume with sinapinic acid (25
mg/mL) in 50% acetonitrile, 49.5% water and 0.5% tri-
fluoroacetic acid, and 1 μL was spotted onto a Pro-
teinChip Gold Array (A-H format) (Bio-Rad Hercules,
CA, USA) and analyzed with a Bio-Rad ProteinChip
System Series 4000 (Enterprise Edition) mass
spectrometer.
Western blotting
TBS, RIPA and 2% SDS brain lysates, heated at 50°C for
three minutes in the presence of denaturing sample buf-
fer, were separated on 4% to 12% Bis-Tris gel (Bio-Rad)
in 1× 2-(N-morpholino)ethanesulfonic acid (MES) run-
ning buffer (Bio-Rad). Initially, we performed a com-
parative analysis of different immunoblotting techniques
with different combinations of membranes (0.2 μm
nitrocellulose and 0.2 μm polyvinylidene fluoride
(PVDF)) and antigen retrieval techniques (boiling, glu-
taraldehyde and guanidine) in combination with three
different primary antibodies (4G8, 82E1 (IBL, Hamburg,
Germany) and Ab5 (human Ab1-16 specific; T.E.
Golde). After extensive analysis samples immunoblotted
with 82E1 on boiled nitrocellulose membranes yielded
the best results in terms of sensitivity and resolution.
Transferred membranes were blocked in Starting Block
(Thermo Scientific, Waltham, MA) and incubated over-
night with primary antibody (82E1) and detected with
donkey anti-mouse antibody conjugated to HRP (Jack-
son ImmunoResearch, West Grove, PA). Chemilumis-
cence signal (West Femto Chemiluminescent Substrate
(Thermo Scientific)) was visualized with a FujiFilm
system.
Statistical analysis
Results, unless otherwise mentioned, were analyzed with
Prism 5 (GraphPad) by one way analysis of variance
(ANOVA) with tukey post hoc test and presented as
Table 1 Summary of demographics of human subjects
studied.
Group
AD (n = 16) PA (n = 8) NDC (n = 7)
Age 82 (66 to 99) 80 (66 to 90) 76 (66 to 87)
Gender
M 8 (50%) 6 (75%) 5 (71%)
F 8 (50%) 2 (25%) 2 (29%)
Braak
2.0 0 (0%) 4 (50%) 4 (57%)
2.5 0 (0%) 1 (13%) 1 (14%)
3.0 0 (0%) 3 (38%) 2 (29%)
3.5 0 (0%) 0 (0%) 0 (0%)
4.0 2 (13%) 0 (0%) 0 (0%)
4.5 2 (13%) 0 (0%) 0 (0%)
5.0 7 (44%) 0 (0%) 0 (0%)
5.5 2 (13%) 0 (0%) 0 (0%)
6.0 3 (19%) 0 (0%) 0 (0%)
CAA
0 6 (38%) 5 (63%) 5 (71%)
0 - 1+ 1 (6%) 0 (0%) 1 (14%)
1+ 6 (38%) 0 (0%) 1 (14%)
1+ - 2+ 1 (6%) 0 (0%) 0 (0%)
2+ 1 (6%) 1 (13%) 0 (0%)
2+ - 3+ 0 (0%) 1 (13%) 0 (0%)
3+ 0 (0%) 1 (13%) 0 (0%)
4+ 1 (6%) 0 (0%) 0 (0%)
Median ages (age range), gender distribution, Braak score and CAA score are
denoted. CAA scoring was done by post-mortem neuropathologic analysis by
DW. AD, Alzheimers disease; CAA, cerebral amyloid angiography; F, female; M,
male; n, number; NDC, non-demented controls; PA, Pathological aging.
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data ± standard error of the mean (s.e.m.). Statistical
significance is denoted by an asterisk.
Results
Immunohistochemical characterization of Ab plaques and
phospho-tau in AD, PA and NDC
The sample population was chosen based on long standing
AD and PA classification systems. Brains selected as PA
had no evidence of cognitive decline in the clinic, but had
extensive cortical Ab plaques (Table 1). To obtain more
extensive characterization of Ab and tau pathology in the
PA cohort, we immunostained frontal cortical tissue for
total Ab, phospho-tau, Ab1-40 (13.1.1) and Ab1-42
(21.3.1) (Figures 1, 2). Consistent with the PA classification
system, PA brains had extensive amyloid deposits and dis-
played only sparse CP13 immunoreactivity whereas AD
patients contained widespread amyloid deposits as well as
abundant phospho-tau bearing neurofibrillary tangles
(Figure 1A, B, C and 1D and 1F, G, H and 1I). PA brains
showed more widespread Ab1-42 immunoreactivity than
Ab1-40 immunoreactivity, perhaps corresponding to more
abundant diffuse plaques as alluded to by independent
groups (Figure 2C, D and 2H, I). Cohorts with increased
vessel-associated Ab1-40 immunoreactivity have been sub-
categorized as having cerebral amyloid angiopathy (CAA);
CAA+ AD patients had more Ab1-40 than the corre-
sponding PA group (Figure 2A, B, C, D, F, G, H and 2I).
Biochemical results of Ab levels in AD, PA and NDC
We analyzed Ab levels from sequentially extracted brain
lysates using four different anti-Ab antibody combina-
tions to detect Ab1-40, Ab1-42, Abtotal and NH2-trun-
cated Abx-42 species (Figure 3). In each of our Ab
ELISAs the detection limit was approximately 0.04
pmol/g. Compared to the 2% SDS and 70% FA extracted
fractions, minimal Ab was detected in the TBS and
Figure 1 Immunohistochemical characterization of amyloid and tau pathology in Alzheimer’s disease (AD), pathological aging (PA)
and normal non-demented controls (NDC). A-E. Representative paraffin embedded formalin fixed hippocampi from human AD (A, B), PA (C,
D) and control (NDC; E) subjects were stained with 33.1.1 antibody (pan Ab1-16). Insets show higher magnification with special emphasis on
cored Ab plaques associated with blood vessels in subjects with a post-mortem clinical pathological diagnosis of cerebral amyloid angiopathy
(CAA+). Scale Bar, 600 μm (A-E), insets 60 μm (A-E). F-J. Representative paraffin embedded formalin fixed hippocampi from human AD (F, G), PA
(H, I) and NDC (J) subjects were stained with anti-phosphorylated tau (CP13). Insets highlight phorphorylated tau containing tangles and neuritic
structures. Scale Bar, 600 μm (A-E), insets 60 μm (A-E). Ab, amyloid b.
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RIPA fractions. For example, in AD extracts the mean
total Ab measured was 1.0, 1.0, 184 and 2,065 pmol/g
for the TBS, RIPA, 2% SDS and 70% FA extracts,
respectively (Figure 3). The levels of total Ab in PA
lysates were 0.8, 0.6, 87 and 1,490 pmol/g for the TBS,
RIPA 2% SDS and 70% FA extracts, respectively (Figure
3). Thus, the sequential solubility of the Ab was similar
in AD and PA. In NDC brain extracts the levels of total
Ab were 0.2, 0.4, 7 and 38 pmol/g for the TBS, RIPA,
2% SDS and 70% FA extracts, respectively (Figure 3).
Thus, a major difference between AD, PA, and controls,
is the dramatic increase in Ab that requires either 2%
SDS or 70% FA to solubilize, suggesting that both AD
and PA cohorts had dramatically increased levels of
insoluble aggregates of Ab.
On average, AD and PA lysates exhibited much higher
levels of Ab than NDC samples, with mean Ab levels in
each PA lysate ranging from almost equivalent to
approximately 50% less than the Ab level detected in
AD lysates (Figure 3). Although not reaching signifi-
cance in each analysis, there were clear differences
between the average levels of Ab in AD and PA extracts
as compared to NDC. There was also extensive overlap
between individual Ab levels in PA and AD as shown in
Additional file 1 Figure S1.
Profiling of Ab peptides by immunoprecipitation/mass
spectrometry (IP/MS)
We next analyzed the lysates by IP/MS to identify var-
ious Ab peptides associated with AD, PA and NDC
cohorts. We used sequential immunoprecipitations
using two non-overlapping anti-Ab antibodies, Ab9
(anti-Ab1-16) followed by 4G8 (anti-Ab17-24), as our
pilot studies suggested that predominant species
Figure 2 Immunohistochemical characterization of Ab1-40 and Ab1-42 in Alzheimer’s disease (AD), pathological aging (PA) and
normal non-demented controls (NDC). A-E. Representative paraffin embedded formalin fixed hippocampi from human AD (A, B), PA (C, D)
and control (NDC; E) subjects were stained with 13.1.1 antibody (Ab35-40). Insets show higher magnification with special emphasis on cored Ab
plaques associated with blood vessels in subjects with a post-mortem clinical pathological diagnosis of cerebral amyloid angiopathy (CAA+).
Scale Bar, 600 μm (A-E), insets 60 μm (A-E). F-J. Representative paraffin embedded formalin fixed hippocampi from human AD (A, B), PA (C, D)
and control (NDC; E) subjects were stained with 2.1.3 antibody (Ab35-42). Insets show higher magnification with special emphasis on cored Ab
plaques associated with blood vessels in subjects with a post-mortem clinical pathological diagnosis of cerebral amyloid angiopathy (CAA+).
Scale Bar, 600 μm (A-E), insets 60 μm (A-E). Ab, amyloid b.
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(detected by Ab9) obscure less abundant peptides, and
that Ab9 does not capture all NH2-terminally truncated
Ab peptides. Spectra from the TBS and RIPA lysates
had low signal to noise ratio attributable to the low
amounts (0 to 4 pmol/g) of Ab in these samples limiting
our ability to definitively identify Ab peptides. In con-
trast, high quality spectra were obtained for the vast
majority of the 2% SDS and 70% FA extracted lysates.
Representative spectra of the 2% SDS and 70% FA
extracts after immunoprecipitation with Ab9 and 4G8
are shown in Figures 4 and 5, respectively. In these
spectra Ab species were assigned to the inferred mass
based on m/z. Numerous COOH- and NH2-terminal
fragments of Ab peptides were observed in a subset of
the lysates from the AD, PA and NDC cohorts; however,
few unique truncated peptides were identified in any
patient group, and these ‘unique’ peptides were only
detected in a minority of the samples in that group.
Unique peptides that 1) have not been previously
reported in other MS analyses of AD brains (for exam-
ple, Ab1-26, 9-40 and 4-40) or 2) that were uniquely
Figure 3 Biochemical analysis of Ab from human brain lysates.
Human prefrontal cortical tissue from Alzheimer’s disease (AD),
pathological aging (PA) and normal controls (NDC) was sequentially
extracted with TBS (A), RIPA (B), 2% SDS (C) and 70% FA (D). End-
specific sandwich ELISAs measuring Ab1-40, Ab1-42, Abtotal and
Abx-42 are presented for each of these fractions. N = 16 (AD), 8
(PA) and 6 (NDC). (***P < 0.001, **P < 0.01, *P < 0.05 by ANOVA
with tukey post-hoc analysis raw data analyzed (A, B) and log-
transformed data analyzed (C, D)). Ab, amyloid b; ANOVA, analysis
of variance; ELISA, enzyme-linked immunosorbent assay; FA, formic
acid; RIPA, radioimmunoprecipitation buffer; SDS, sodium dodecyl
sulfate; TBS, Tris buffered saline.
Figure 4 Mass spectrometric (MS) analysis following
immunoprecipiation of Ab from 2% SDS extracted lysates of
human subjects. 2% SDS lysates of Alzheimer’s disease (AD; A, D),
pathological aging (PA; B, E) and control (NDC; C, F) subjects were
subjected to immunoprecipitation with pull-down by Ab9 (A-C),
sequential pull-down with Ab9 and 4G8 (D-F). Representative MS
spectra are shown (A-F). Peaks corresponding to Ab peptides have been
labeled according to m/z. Ab1-28 was spiked in as an experimental
control. The 1-42* peak denotes a possible modified Ab1-42 species
(Ab1-42 + 16 Da, A-E). Ab, amyloid b; SDS, sodium dodecyl sulfate.
Figure 5 Mass spectrometric (MS) analysis following
immunoprecipiation of Ab peptides from 70% formic acid
extracted lysates of human subjects. 70% formic acid extracted
lysates of Alzheimer’s disease (AD; A, D), pathological aging (PA; B, E)
and control (NDC; C, F) cohorts were subjected to
immunoprecipitation with pull-down by Ab9 (A-C), sequential pull-
down with Ab9 and 4G8 (D-F). Representative MS spectra are shown.
Peaks corresponding to Ab peptides have been labeled according to
m/z. Ab1-28 was spiked in as an experimental control. Different peaks
corresponding to modified Ab are shown (4-42*, Ab4-42 + 16 Da; 1-
40*, Ab1-40 +16 Da; 1-42**, Ab1-42 + 22 Da). Ab, amyloid b.
Moore et al. Alzheimer’s Research & Therapy 2012, 4
:18
present in PA (for example, Ab1-22, 4-42 and 11-42),
AD (for example, Ab8-40, 1-37, 1-38 and 1-39) or NDC
(for example, Ab1-26, 1-27 and 2-42) are distinguished
in Tables 2, 3, 4 and 5 by differential fonts. Though the
profiles were overlapping between AD, PA and NDC
samples (Figures 4, 5, 6 and 7; Tables 2, 3, 4 and 5),
there were more complex mixtures of Ab peptides
observed in a subset of the AD samples versus PA and
for most of the AD and PA samples relative to control.
These differences typically related to minor peaks in a
subset of the spectra. This did not appear to be related
to absolute levels of Ab as they were similar to levels
measured by ELISAs in the starting extracts. Notably,
consistent with many previous studies, Ab1-42 was the
only species consistently detected by the Ab9 IP/MS in
all AD and PA brains.
Several modified Ab peptides, that were consistent
with a 16 Da increase in mass, were observed. This
mass shift is typically indicative of oxidation. Control
studies demonstrated that the methodology used did not
induce oxidation of reduced synthetic Ab. Thus, there
was evidence that Ab1-30, 1-37, 1-38, 1-40 and 1-42
were present in the brain as oxidized species. In most
cases the peptides were detected in only a few samples
among the cohort sets and there were no notable differ-
ences in the rate of detection between AD, PA and con-
trols. However, oxidized Ab peptides were detected
more frequently in AD cases with CAA (ten of ten)
Table 2 Mass spectrometric analysis of SDS soluble fraction immunoprecipitated with Ab9 from human brains reveal
unique Ab peaks.
Ab Peptide predicted MW observed MW AD (n = 16) PA (n = 9) NDC (n = 8)
1-22 2661.82 2663.37 1 (11.1%)
1-26 3020.16 3021.17 3 (18.8%) 3 (33.3%)
8-40 3458.98 3461.27 1 (6.3%)
9-40 3371.90 3372.80 2 (22.2%) 1 (12.5%)
4-40 4014.57 4016.50 1 (6.3%) 1 (11.1%)
5-42 4051.57 4053.50 1 (6.3%)
1-38 4131.52 4133.95 1 (6.3%)
4-42 4198.74 4200.44 7 (43.8%) 3 (33.3%) 2 (25%)
1-39 4230.65 4233.33 1 (6.3%)
1-40 4329.78 4331.96 10 (62.5%) 3 (33.3%) 2 (25%)
1-40 +16 Da 4345.78 4345.96 1 (11.1%) 2 (25%)
1-41 4442.94 4446.86 1 (6.3%)
2-43 4500.11 4503.58 1 (6.3%)
1-42 4514.02 4516.48 16 (100%) 9 (100%) 5 (62.5%)
1-42 +16 Da 4530.02 4531.81 8 (50%) 3 (33.3%) 2 (25%)
1-43 4615.20 4616.60 3 (18.8%) 1 (11.1%) 1 (12.5%)
Human brain tissue was extracted with 2% SDS and sequentially immunoprecipitated with Ab9 and 4G8 antibodies to enrich different truncated or modified Ab
peptides. Mass spectrometric analysis shows unique Ab peptides that 1) have not been previously reported in other mass spectrometric analyses of AD brains
(underlined) 2) uniquely present in AD (bold font) or PA (italicized) are differentially highlighted. Predicted molecular weights and observed molecular weights
have been calculated using ExPASy PeptideMass and ProteinChip Data Manager software (Bio-Rad), respectively. The number of subjects (AD, Alzheimer’s disease;
PA, Pathological aging; NDC, controls) displaying each uniquely identifiable Ab peptides and the percentage of occurrence of such peptides corresponding to the
total sample size is denoted. Ab, amyloid b; MW, molecular weight; n, number; SDS, sodium dodecyl sulfate.
Table 3 Mass spectrometric analysis of SDS soluble fraction immunoprecipitated with 4G8 from human brains reveal
unique Ab peaks.
Ab Peptide predicted MW observed MW AD (n = 16) PA (n = 9) NDC (n = 8)
8-40 3458.98 3462.81 1 (6.3%)
4-40 4014.57 4018.49 1 (6.3%)
4-42 4198.74 4202.62 4 (25.0%) 3 (33.39%) 1 (12.5%)
1-40 4329.78 4333.49 3 (18.8%) 1 (12.5%)
1-42 4514.02 4516.74 9 (56.3%) 7 (77.80%) 2 (25%)
1-42 +16 Da 4530.02 4534.90 2 (12.5%) 2 (22.2%) 2 (25%)
Human brain tissue was extracted with 2% SDS and sequentially immunoprecipitated with Ab9 and 4G8 antibodies to enrich different truncated or modified Ab
peptides. Mass spectrometric analysis shows unique Ab peptides that 1) have not been previously reported in other mass spectrometric analyses of AD brains
(underlined) 2) uniquely present in AD (bold font) are differentially highlighted. Predicted molecular weights and observed molecular weights have been
calculated using ExPASy PeptideMass and ProteinChip Data Manager software (Bio-Rad), respectively. The number of subjects (AD, Alzheimer’s disease; PA,
Pathological aging; NDC, controls) displaying each uniquely identifiable Ab peptide and the percentage of occurrence of such peptides corresponding to the
total sample size is denoted. Ab, amyloid b; MW, molecular weight; n, number; SDS, sodium dodecyl sulfate.
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compared to cases without CAA (one of six). This asso-
ciation was not apparent in PA where oxidized Ab pep-
tides were detected in two of four cases with and three
of five cases without CAA. Three peaks, consistent with
pyroglutamate Ab, were detected in the 70% FA fraction
of AD, PA and controls: AbpE11-40, AbpE11-42 and
AbpE3-42. These species were not detected in the 2%
SDS lysates suggesting that they are highly insoluble.
Immunoblotting analysis of Ab species
We next analyzed these samples by SDS-PAGE followed
by Western Blot. The representative blots shown were
separated by electrophoresis, transferred to nitrocellu-
lose, not boiled and stained with 82E1 antibody (anti-
Ab1-16) (IBL). We found that this method gave the
most sensitive detection and, based on estimates, our
detection limit was 1 to 10 pmol monomeric Ab. A
number of Western Blots failed to differentiate oligomer
assemblies between PA and AD in TBS and 2% SDS
lysates (Figure 8) and RIPA lysates (Figure 9). We
detected a 10 kDa band in the TBS and RIPA lysates of
AD, PA and NDC cohorts. This band could be an oligo-
meric assembly of Ab, an APP b-C-terminal fragment
(since there is cross-reactivity of these two species with
82E1) or a non-specific band. This band was consis-
tently detected with other anti-Ab antibodies, although
these other antibodies had lower limits of sensitivity.
Discussion
In this study we systematically characterized Ab levels
and solubility, peptide profiles and oligomeric assemblies
in a postmortem series of PA, AD and NDC cohorts.
Using a panel of Ab sandwich ELISAs we appraised the
levels of Ab1-40, Ab1-42 and Abtotal, as well as Abx-
42. We found extensive overlap in Ab levels between
AD and PA brains. On average, AD and PA lysates con-
tained much more Ab than NDC samples. Ab levels in
PA lysates were similar to the levels in the AD lysates,
ranging from almost equivalent to approximately 50%
less than the Ab detected in AD lysates and solubility
profiles were similar with the vast majority of Ab in PA
and AD requiring either SDS or FA to solubilize.
Table 4 Mass spectrometric analysis of formic acid (FA) fraction immunoprecipitated with Ab9 from human brains
reveal unique Ab peaks.
Ab Peptide predicted MW observed MW AD (n = 16) PA (n = 9) NDC (n = 8)
1-18 2167.28 2167.70 2 (12.5%)
1-26 3020.16 3021.02 2 (25%)
pE11-40 3115.65 3151.47 1 (12.5%)
1-27 3134.27 3134.77 1 (12.5%)
pE11-42 3317.90 3318.91 1 (6.3%) 2 (22.2%)
9-40 3371.90 3372.97 8 (50%) 6 (66.7%) 5 (62.5%)
1-30 +16 Da 3406.57 3409.22 1 (6.3%)
1-36 4017.42 4019.60 1 (6.3%)
1-37 4074.47 4076.58 2 (12.5%)
1-37 +16 Da 4090.47 4094.07 1 (6.3%)
1-38 4131.52 4134.52 4 (25.0%)
1-38 + 16 Da 4147.52 4150.11 1 (6.3%)
4-42 4198.74 4200.32 2 (22.2%)
4-42 +16 Da 4214.74 4216.78 1 (6.3%) 1 (11.1%) 1 (12.5%)
1-39 4230.65 4232.14 2 (12.5%) 1 (11.1%)
3-41 4256.85 4260.60 2 (12.5%) 1 (11.1%)
pE3-42 4309.90 4312.76 1 (11.1%)
1-40 4329.78 4332.14 12 (75.0%) 6 (66.7%) 2 (25%)
1-40 +16 Da 4345.78 4347.41 7 (43.8%) 1 (11.1%) 1 (12.5%)
2-42 4395.93 4399.63 1 (12.5%)
1-41 4442.94 4444.51 1 (6.3%) 1 (11.1%)
1-42 4514.02 4516.58 16 (100%) 9 (100%) 4 (50%)
1-42 +16 Da 4530.02 4532.13 9 (56.3%) 4 (44.4%) 1 (12.5%)
1-43 4615.20 4617.58 4 (25.0%) 3 (33.3%) 1 (12.5%)
Human brain tissue, extracted with 70% FA, was sequentially immunoprecipitated with Ab9 and 4G8 antibodies to enrich different truncated or modified Ab
species. Mass spectrometric analysis shows unique Ab peptides that 1) have not been previously reported in other mass spectrometric analyses of AD brains
(underlined) 2) uniquely present in AD (bold font), PA (italicized font) or controls (bold and italicized font) are differentially highlighted. Predicted molecular
weights and observed molecular weights have been calculated using ExPASy PeptideMass and ProteinChip Data Manager software (Bio-Rad), respectively. The
number of subjects (AD, Alzheimer’s. disease; PA, Pathological aging; NDC, controls) displaying each uniquely identifiable Ab peptide and the percentage of
occurrence of such peptide corresponding to the total sample size is denoted. Ab, amyloid b; MW, molecular weight; n, number.




We examined Ab peptide profiles by IP/MS in AD,
PA and NDC patient brain lysates. Ab1-42 was identi-
fied as the predominant peak in the SDS and FA ‘insolu-
ble’ fractions across all groups. As noted above, it was
the only Ab peptide detected by IP/MS in all PA and
AD cases. In addition, several unique NH2- and COOH-
terminal truncated Ab peptides were observed in the
AD brain lysates. However, few unique truncated Ab
peptides were observed in any one patient group and
these peptides represented minor peaks. These trun-
cated peptides may represent alternate cleavage products
by b- and g-secretases or products of Ab degradation.
Interestingly, we detected peaks that correspond to
Ab1-30, 1-37, 1-38, 1-40 and 1-42 with a 16 Da mass
shift that we hypothesize to be oxidation products of
Ab. Oxidation of these Ab peptides could be an artifact
due to the extraction and IP/MS techniques utilized in
this study; however, this is unlikely since we did not
observe the mass shift in other detected Ab peptides or
in control IP/MS studies using reduced synthetic Ab.
Although Ab is composed of several amino acids that
could be oxidized, most studies have suggested oxida-
tion occurs primarily at the methionine residue at posi-
tion 35 (Met-35) [40]. A number of studies suggest that
oxidized Ab peptides are present in the brain and that
oxidation of Ab1-42 decreases the rate of aggregation,
disrupts fibril morphology and inhibits oligomerization
[41,42]. Oxidized Ab peptides were observed as minor
peaks in the spectra, indicating that these represent a
minor fraction of total Ab since control studies showed
that both peptides ionized at the same levels. There
were no striking differences in oxidized peptides
between AD and PA patients. However, remarkably all
of the AD patients with CAA had oxidized Ab peptides
while only one of six AD patients without CAA had oxi-
dized Ab peptides.
We detected peaks corresponding to pyroglutamate
modified Ab (AbpE), at position 11, AbpE11-40,
Table 5 Mass spectrometric analysis of formic acid (FA) fraction immunoprecipitated with 4G8 from human brains
reveal unique Ab peaks.
Ab Peptide predicted MW observed MW AD (n = 16) PA (n = 9) NDC (n = 8)
1-18 2167.28 2165.21 1 (6.3%)
1-27 3134.27 3135.30 1 (6.3%)
E11-42 3317.90 3320.02 8 (50.0%) 7 (77.8%) 1 (12.5%)
1-29 3319.49 3320.87 1 (6.3%)
11-42 3335.90 3328.79 1 (11.1%)
9-40 3371.90 3373.39 3 (18.8%) 5 (55.6%) 4 (50%)
8-40 3458.98 3460.65 1 (6.3%) 1 (11.1%)
1-31 3503.72 3503.55 1 (6.3%)
9-42 3556.08 3557.85 1 (6.3%)
8-42 3643.15 3644.86 5 (31.3%) 1 (12.5%)
7-42 3758.24 3758.89 2 (12.5%)
1-34 3787.09 3786.56 1 (6.3%)
1-35 3918.29 3918.96 1 (6.3%)
4-40 4014.57 4016.85 1 (6.3%) 1 (11.1%)
1-36 4017.42 4018.25 1 (6.3%) 1 (11.1%)
5-42 4051.57 4053.59 4 (25.0%) 1 (12.5%)
1-37 4074.47 4075.25 1 (6.3%)
1-38 4131.52 4131.33 1 (6.3%) 1 (11.1%)
4-42 4198.74 4201.29 5 (55.6%) 2 (25%)
4-42 +16 Da 4214.74 4217.09 2 (12.5%) 1 (11.1%)
1-39 4230.65 4231.46 1 (6.3%)
E3-42 4309.90 4312.76 4 (25.0%) 3 (33.3%) 1 (12.5%)
1-40 4329.78 4331.85 8 (50.0%) 5 (55.6%) 2 (25%)
1-40 +16 Da 4345.78 4348.09 4 (25.0%)
1-42 4514.02 4516.70 10 (62.5%) 7 (77.8%) 4 (50%)
1-42 +16 Da 4530.02 4533.03 1 (12.5%)
Human brain tissue, extracted with 70% FA, was sequentially immunoprecipitated with Ab9 and 4G8 antibodies to enrich different truncated or modified Ab
species. Mass spectrometric analysis shows unique Ab peptides that 1) have not been previously reported in other mass spectrometric analyses of AD brains
(underlined) 2) uniquely present in AD (bold font), PA (italicized font) or controls (bold and italicized font) are differentially highlighted. Predicted molecular
weights and observed molecular weights have been calculated using ExPASy PeptideMass and ProteinChip Data Manager software (Bio-Rad), respectively. The
number of subjects (AD, Alzheimer’s disease; PA, Pathological aging; NDC, controls) displaying each uniquely identifiable Ab peptide and the percentage of
occurrence of such peptide corresponding to the total sample size is denoted. Ab, amyloid b; MW, molecular weight; n, number.
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AbpE11-42, and at position 3, AbpE3-42, in the insolu-
ble lysates of AD, PA and NDC. AbpE is formed by glu-
tamate cyclization at position 11 by glutaminyl cyclase
[43]. The conversion of glutamate to pyroglutamate is
reported to protect the Ab peptide from degradation
through resistance to aminopeptidases [44]. AbpE is also
reported to be highly prone to oligomerization and can
possibly seed the oligomerization and fibrillation process
of full-length Ab species [18,20,45]. Based on these data
as well as other studies examining AbpE levels and ani-
mal modeling studies that manipulate AbpE levels, an
initiating role for AbpE in AD has been proposed
[46-50]. Although our detection of AbpE in a control
brain would not be inconsistent with a postulated role
in seeding aggregation, its presence in some PA brains
suggest that its toxicity is not inherently different from
other aggregated Ab peptides.
There is currently much debate regarding which types
of Ab aggregates are the most toxic. Ab rapidly forms
stable fibrillar amyloid structures, which account for
much of the Ab that accumulates in the AD brain. Over
the last decade, a variety of soluble oligomeric species,
including dimers, trimers, tetramers and 10-12-mers
have been identified and isolated [35,51-53]. These oli-
gomers have been shown to be biologically active as
they inhibit hippocampal long-term potentiation and
create memory impairments when injected into rodents
[35,53,54]. Additional circumstantial data suggests that
oligomeric assemblies may account for some of the
behavioral deficits observed in APP mice [55]. As there
Figure 6 Summary of SDS soluble Ab peptides in test subjects. 2% SDS extracted lysates from human prefrontal cortical tissues were
subjected to immunoprecipitation with pull-down by Ab9 (A) or sequential pull-down with Ab9 and 4G8 (B), followed by MS. Data are
graphically presented as a percentage of subjects in each cohort (Alzheimer’s disease (AD), Pathological aging (PA) or controls (NDC)) containing
Ab peptides (x-axis). N = 16 (AD), 8 (PA) and 6 (NDC). Ab, amyloid b; MS, mass spectrometry; N, number; SDS, sodium dodecyl sulfate.
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is no standard methodology to detect oligomeric assem-
blies, we empirically settled on a method that was the
most sensitive in our hands, and also would enable us
to survey oligomeric assemblies in multiple brain lysates.
This survey revealed that there were no obvious differ-
ences in higher molecular weight bands between AD,
PA and NDC. Our data are consistent with a recent
publication that reported a more extensive analysis of
oligomeric assemblies and also failed to detect major
differences in PA and AD [34]. Indeed, it is not the rela-
tively small increases in the TBS and RIPA extractable
Ab pools but that of the SDS and 70% FA extractable
insoluble Ab pools that clearly distinguish both AD and
PA from controls.
Conclusions
In summary, we investigated Ab levels, peptides and
assemblies from soluble, detergent-soluble and insoluble
pools from AD, PA and NDC brain. We found only
subtle quantitative differences between PA and AD
brains that, in most cases, did not reach significance.
We found overlap between the PA and AD Ab peptide
profile, as examined by IP/MS, but AD patients con-
tained additional amino terminal truncated Ab peptides.
There were no major differences observed in SDS-stable
Ab oligomeric assemblies. We cannot rule out the possi-
bility that there are conformational differences or very
subtle differences in minor Ab peptides or assemblies
that distinguish AD from PA; however, our data, which
shows extensive similarities between deposited Ab in
AD and PA, would indicate that PA is not likely to
represent a form of benign Ab deposition. Indeed, our
data are more consistent with the hypothesis that PA
represents an initial prodromal stage of AD and that
these individuals would eventually go on to develop
clinical symptoms, if they live long enough [31,32].
Figure 7 Summary of formic acid soluble Ab peptides in test subjects. 70% FA extracted lysates from human prefrontal cortical tissue were
subjected to immunoprecipitation with pull-down by Ab9 (A) or sequential pull-down with Ab9 and 4G8 (B), followed by MS. Data are
graphically presented as a percentage of subjects in each cohort (Alzheimer’s disease (AD), Pathological aging (PA) or controls (NDC)) containing
Ab peptides (x-axis). N = 16 (AD), 8 (PA) and 6 (NDC). Ab, amyloid b; FA, formic acid; MS, mass spectrometry; N, number.
Moore et al. Alzheimer’s Research & Therapy 4
:18
http://alzres.com/content/4/3/18
Notably, PA brains do not completely lack cortical tau
pathology; however, pathological phospho-tau levels are
present in lower levels compared to AD (Figure 1).
Indeed, given predictions of the amyloid cascade
hypothesis, many of which are being demonstrated in
living humans via imaging and cerebrospinal fluid stu-
dies, one would predict that a subset of cognitively nor-
mal subjects would die with heavy amyloid loads but
limited tau pathology [56,57]. This possibility needs to
be taken into account in the debate regarding identifica-
tion of the toxic Ab species. We should not discount
the role of insoluble fibrillar assemblies in driving down-
stream pathologies; assemblies may produce an insidious
form of cellular toxicity that may be difficult to assess in
more acute experimental models. This concept may best
be phrased that amyloid-like assemblies are necessary
Figure 8 Immunoblot analysis of Ab species from sequentially
extracted human prefrontal cortical tissue lysates. Human
hippocampi from Alzheimer’s disease (AD), pathological aging (PA)
and normal (N) cohorts were sequentially extracted with TBS, 2% SDS
extracted lysates from human subjects. Representative immunoblots
probed with 82E1 antibody are shown. Control lanes includes cell
lysates expressing C99 (CTFb) and recombinant Ab1-42 (43 pmol). Ab,
amyloid b; SDS, sodium dodecyl sulfate; TBS, Tris buffered saline.
Figure 9 Immunoblot analysis of Ab species from RIPA soluble
lysates from human subjects. Human hippocampi from
Alzheimer’s disease (AD), pathological aging (PA) and normal (N)
cohorts were extracted with RIPA. Representative anti-82E1
immunoblot of RIPA extracted lysates of Alzheimer’s disease (AD),
pathologic aging (PA) and control (N) subjects with (A) and without
(B) a post-mortem clinical pathological diagnosis of cerebral
amyloid angiopathy (+CAA). Longer exposure panels below
highlight no significant differences between the three cohorts in
the dimer/trimer molecular weight range. Ab, amyloid b; RIPA,
radioimmunoprecipitation buffer.
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but not sufficient to drive neurodegeneration. Although
speculative, it is also possible that PA patients may be
protected from the downstream effects of Ab. In the lat-
ter case, genetic studies, gene expression profiling, or
perhaps even development of induced pluripotent stem
cells from PA subjects could identify factors that confer
protection from Ab. Ultimately, in order to determine
whether PA represents a prodromal phase of AD or
could reflect inherent resistance to Ab, long-term longi-
tudinal amyloid imaging, biomarker studies, and post-
mortem neuropathological examination will be needed.
If powered sufficiently such studies could determine
whether there are subsets of individuals who develop
AD-like plaque pathology but retain normal cognitive
function without neurodegeneration after extended peri-
ods of time or whether parenchymal Ab accumulation
invariably leads to neurodegeneration and AD.
Additional material
Additional file 1: Figure S1. Biochemical analysis of Ab levels from
human brain lysates. A panel of sandwich ELISAs measuring Ab1-40,
Ab1-42, Abtotal and Abx-42 from brain lysates sequentially extracted
with TBS (A), RIPA (B), 2% SDS (C) and 70% formic acid (D) is shown.
Data are presented as scatter dot plots, n = 16 (AD), 8 (PA) and 6 (NDC).
(***P < 0.001, **P < 0.01, *P < 0.05 by ANOVA with tukey post-hoc
analysis raw data analyzed (A, B) and log-transformed data analyzed (C,
D)).
Abbreviations
Aβ: amyloid-beta; AD: Alzheimer’s disease; APP: amyloid β protein precursor;
CAA: cerebral amyloid angiopathy; ELISA: enzyme-linked immunosorbent
assay; FA: formic acid; HRP: horseradish peroxidase; IP/MS:
immunoprecipitation/mass spectrometry; mAb: monoclonal antibody; PA:
pathological aging; NDC: non-demented controls; RIPA:
radioimmunoprecipitation buffer; SDS: sodium dodecyl sulfate; TBS: Tris
buffered saline.
Acknowledgements
We are grateful to all patients, family members and caregivers who agreed
to brain donation, without which these studies would not have been
possible. We also acknowledge the expert technical assistance of Monica
Casey-Castanedes, Linda Rousseau and Virginia Phillips for
immunohistochemistry and for histology. This research was funded by the
Mayo Clinic Alzheimer’s Disease Research Center Pilot Project Grant
(AG16574) and the NIH AG20206 (TEG).
Author details
1Center for Translational Research in Neurodegenerative Disease,
Department of Neuroscience, McKnight Brain Institute, College of Medicine,
University of Florida, 1275 Center Drive, Gainesville, FL, 32610, USA.
2Department of Pharmacology, Emory University School of Medicine, 1510
Clifton Road, Atlanta, GA, 30322, USA. 3Department Of Neuroscience, Mayo
Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL, 32224,
USA.
Authors’ contributions
BDM, TEG and PD conceived and designed the study. DWD provided
human samples and contributed to critical discussions. BDM, PC, AMB, TM
and TL prepared samples and acquired data. BDM and TEG drafted the
manuscript. BDM, PC, YL, TK, PD and TEG contributed to the interpretation
of findings. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
References
1. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P:
Correlations of synaptic and pathological markers with cognition of the
elderly. Neurobiol Aging 1995, 16:285-298, discussion 298-304.
2. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH,
Aronson MK: Identification of normal and pathological aging in
prospectively studied nondemented elderly humans. Neurobiol Aging
1992, 13:179-189.
3. Golde TE, Dickson DW, Hutton M: Filling the gaps in the Ab cascade
hypothesis of Alzheimer’s disease. Curr Alz Res 2006, 3:421-430.
4. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-
Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H,
Jicha GA, Mequro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S,
Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P: Revising the
definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010,
9:1118-1127.
5. Reinhard C, Hebert SS, De Strooper B: The amyloid-beta precursor protein:
integrating structure with biological function. Embo J 2005, 24:3996-4006.
6. De Strooper B, Vassar R, Golde T: The secretases: enzymes with
therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010, 6:99-107.
7. Lewis PA, Perez-Tur J, Golde TE, Hardy J: The presenilin 1 C92S mutation
increases abeta 42 production. Biochem Biophys Res Commun 2000,
277:261-263.
8. Wang R, Sweeney D, Gandy SE, Sisodia SS: The profile of soluble amyloid
beta protein in cultured cell media. Detection and quantification of
amyloid beta protein and variants by immunoprecipitation-mass
spectrometry. J Biol Chem 1996, 271:31894-31902.
9. Younkin SG: The role of A beta 42 in Alzheimer’s disease. J Physiol Paris
1998, 92:289-292.
10. Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N,
Matsuba Y, Yamada K, Nilsson P, Takano J, Nishimura M, Iwata N, Van
Broeckhoven C, Ihara Y, Saido TC: Potent amyloidogenicity and
pathogenicity of Abeta43. Nat Neurosci 2011, 14:1023-1032.
11. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P,
Otto M, Kornhuber J, Wiltfang J: Amyloid beta peptides in cerebrospinal
fluid as profiled with surface enhanced laser desorption/ionization time-
of-flight mass spectrometry: evidence of novel biomarkers in
Alzheimer’s disease. Biol Psychiatry 2004, 55:524-530.
12. Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M,
Maler JM, Ruther E, Kornhuber J, Wiltfang J: The amyloid-beta (Abeta)
peptide pattern in cerebrospinal fluid in Alzheimer’s disease: evidence
of a novel carboxyterminally elongated Abeta peptide. Rapid Commun
Mass Spectrom 2003, 17:1291-1296.
13. Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H,
Beyermann M, Schleuder D, Jahn H, Ruther E, Kornhuber J, Annaert W, De
Strooper B, Saftiq P: Elevation of beta-amyloid peptide 2-42 in sporadic
and familial Alzheimer’s disease and its generation in PS1 knockout
cells. J Biol Chem 2001, 276:42645-42657.
14. Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C:
Oxidation of Abeta and plaque biogenesis in Alzheimer’s disease and
Down syndrome. Neurobiol Dis 2001, 8:792-806.
15. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO,
Silberring J, Gandy SE, Winblad B, Greengard P, Nordstedt C, Terenius L:
Relative abundance of Alzheimer A beta amyloid peptide variants in
Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994,
91:8378-8382.
16. Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, Kalback WM,
Luehrs DC, Vishnivetskaya TA, Abramowski D, Sturchler-Pierrat C,
Staufenbiel M, Weller RO, Roher AE: The evolution of A beta peptide
burden in the APP23 transgenic mice: implications for A beta deposition
in Alzheimer disease. Mol Med 2001, 7:609-618.
17. Boutte AM, Woltjer RL, Zimmerman LJ, Stamer SL, Montine KS, Manno MV,
Cimino PJ, Liebler DC, Montine TJ: Selectively increased oxidative
modifications mapped to detergent-insoluble forms of Abeta and beta-
III tubulin in Alzheimer’s disease. FASEB J 2006, 20:1473-1483.
Moore et al. Alzheimer’s Research & Therapy 2012, 4
:184
http://alzres.com/content/4/3/18
18. He W, Barrow CJ: The A beta 3-pyroglutamyl and 11-pyroglutamyl
peptides found in senile plaque have greater beta-sheet forming and
aggregation propensities in vitro than full-length A beta. Biochemistry
1999, 38:10871-10877.
19. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U,
D’Arrigo C, Patrone E, Carlo P, Schettini G: Pyroglutamate-modified
amyloid beta-peptides–AbetaN3(pE)–strongly affect cultured neuron and
astrocyte survival. J Neurochem 2002, 82:1480-1489.
20. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G,
Demuth HU: On the seeding and oligomerization of pGlu-amyloid
peptides (in vitro). Biochemistry 2006, 45:12393-12399.
21. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA:
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration
and lethal neurological deficits in a transgenic mouse model. Acta
Neuropathol 2009, 118:487-496.
22. Hartlage-Rubsamen M, Morawski M, Waniek A, Jager C, Zeitschel U, Koch B,
Cynis H, Schilling S, Schliebs R, Demuth HU, Rossner S: Glutaminyl cyclase
contributes to the formation of focal and diffuse pyroglutamate (pGlu)-
Abeta deposits in hippocampus via distinct cellular mechanisms. Acta
Neuropathol 2011, 121:705-719.
23. Harper JD, Lansbury PT Jr: Models of amyloid seeding in Alzheimer’s
disease and scrapie: mechanistic truths and physiological consequences
of the time-dependent solubility of amyloid proteins. Annu Rev Biochem
1997, 66:385-407.
24. Lomakin A, Teplow DB, Kirschner DA, Benedek GB: Kinetic theory of
fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci USA 1997,
94:7942-7947.
25. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science 2002,
297:353-356.
26. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB,
Selkoe DJ: Protofibrillar intermediates of amyloid beta-protein induce
acute electrophysiological changes and progressive neurotoxicity in
cortical neurons. J Neurosci 1999, 19:8876-8884.
27. Klein WL, Krafft GA, Finch CE: Targeting small Abeta oligomers: the
solution to an Alzheimer’s disease conundrum? Trends Neurosci 2001,
24:219-224.
28. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T,
Younkin LH, Carlson GA, Younkin SG, Ashe KH: The relationship between
Abeta and memory in the Tg2576 mouse model of Alzheimer’s disease.
J Neurosci 2002, 22:1858-1867.
29. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW,
Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG: Dimeric amyloid
beta protein rapidly accumulates in lipid rafts followed by
apolipoprotein E and phosphorylated tau accumulation in the Tg2576
mouse model of Alzheimer’s disease. J Neurosci 2004, 24:3801-3809.
30. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L,
Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R,
Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T: Abeta42 is essential
for parenchymal and vascular amyloid deposition in mice. Neuron 2005,
47:191-199.
31. Golde TE, Schneider LS, Koo EH: Anti-abeta therapeutics in Alzheimer’s
disease: the need for a paradigm shift. Neuron 2011, 69:203-213.
32. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS,
Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC: Serial
PIB and MRI in normal, mild cognitive impairment and Alzheimer’s
disease: implications for sequence of pathological events in Alzheimer’s
disease. Brain 2009, 132:1355-1365.
33. Wang J, Dickson DW, Trojanowski JQ, Lee VM: The levels of soluble versus
insoluble brain Abeta distinguish Alzheimer’s disease from normal and
pathologic aging. Exp Neurol 1999, 158:328-337.
34. Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, Kruchowsky JC,
Woltjer R, Kaye J, Castano EM, Sabbagh MN, Beach TG, Roher AE:
Alzheimer’s disease and non-demented high pathology control
nonagenarians: comparing and contrasting the biochemistry of
cognitively successful aging. PLoS One 2011, 6:e27291.
35. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I,
Brett FM, Farrell MA, Rowan MJ, Lemere CA, Walsh DM, Sabatini BL,
Selkoe DJ: Amyloid-beta protein dimers isolated directly from
Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008,
14:837-842.
36. Saido TC, Yokota M, Tani E, Kawashima S: Alzheimer’s Disease: Biology,
Diagnosis and Therapeutics New York: Wiley; 1997.
37. Schmidt ML, DiDario AG, Otvos L Jr, Hoshi N, Kant JA, Lee VM,
Trojanowski JQ: Plaque-associated neuronal proteins: a recurrent motif in
neuritic amyloid deposits throughout diverse cortical areas of the
Alzheimer’s disease brain. Exp Neurol 1994, 130:311-322.
38. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG: Age-
dependent changes in brain, CSF, and plasma amyloid (beta) protein in
the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci
2001, 21:372-381.
39. Kim J, Miller VM, Levites Y, West KJ, Zwizinski CW, Moore BD, Troendle FJ,
Bann M, Verbeeck C, Price RW, Smithson L, Sonoda L, Wagg K,
Rangachari V, Zou F, Younkin SG, Graff-Radford N, Dickson D, Rosenberry T,
Golde TE: BRI2 (ITM2b) inhibits Abeta deposition in vivo. J Neurosci 2008,
28:6030-6036.
40. Butterfield DA, Kanski J: Methionine residue 35 is critical for the oxidative
stress and neurotoxic properties of Alzheimer’s amyloid beta-peptide 1-
42. Peptides 2002, 23:1299-1309.
41. Hou L, Kang I, Marchant RE, Zagorski MG: Methionine 35 oxidation
reduces fibril assembly of the amyloid abeta-(1-42) peptide of
Alzheimer’s disease. J Biol Chem 2002, 277:40173-40176.
42. Bitan G, Tarus B, Vollers SS, Lashuel HA, Condron MM, Straub JE, Teplow DB:
A molecular switch in amyloid assembly: Met35 and amyloid beta-
protein oligomerization. J Am Chem Soc 2003, 125:15359-15365.
43. Cynis H, Scheel E, Saido TC, Schilling S, Demuth HU: Amyloidogenic
processing of amyloid precursor protein: evidence of a pivotal role of
glutaminyl cyclase in generation of pyroglutamate-modified amyloid-
beta. Biochemistry 2008, 47:7405-7413.
44. Tekirian TL, Yang AY, Glabe C, Geddes JW: Toxicity of pyroglutaminated
amyloid beta-peptides 3(pE)-40 and -42 is similar to that of A beta1-40
and -42. J Neurochem 1999, 73:1584-1589.
45. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG: Amyloid
beta protein starting pyroglutamate at position 3 is a major component
of the amyloid deposits in the Alzheimer’s disease brain. Biochem
Biophys Res Commun 2000, 276:422-427.
46. Schieb H, Kratzin H, Jahn O, Mobius W, Rabe S, Staufenbiel M, Wiltfang J,
Klafki HW: Beta-amyloid peptide variants in brains and cerebrospinal
fluid from amyloid precursor protein (APP) transgenic mice: comparison
with human Alzheimer amyloid. J Biol Chem 2011, 286:33747-33758.
47. Jawhar S, Wirths O, Bayer TA: Pyroglutamate amyloid-beta (Abeta): a
hatchet man in Alzheimer disease. J Biol Chem 2011, 286:38825-38832.
48. Jawhar S, Wirths O, Schilling S, Graubner S, Demuth HU, Bayer TA:
Overexpression of glutaminyl cyclase, the enzyme responsible for
pyroglutamate A{beta} formation, induces behavioral deficits, and
glutaminyl cyclase knock-out rescues the behavioral phenotype in
5XFAD mice. J Biol Chem 2011, 286:4454-4460.
49. Alexandru A, Jagla W, Graubner S, Becker A, Bauscher C, Kohlmann S,
Sedlmeier R, Raber KA, Cynis H, Ronicke R, Reymann KG, Petrasch-Parwez E,
Hartlage-Rubsamen M, Waniek A, Rossner S, Schilling S, Osmand AP,
Demuth HU, von Horsten S: Selective hippocampal neurodegeneration in
transgenic mice expressing small amounts of truncated Abeta is
induced by pyroglutamate-Abeta formation. J Neurosci 2011,
31:12790-12801.
50. Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B,
Demuth HU, Blennow K, Wirths O, Bayer TA: Pyroglutamate A(beta)
aggravates behavioral deficits in 5XFAD mice. J Biol Chem 2012,
287:8154-8162.
51. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ,
Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently
inhibit hippocampal long-term potentiation in vivo. Nature 2002,
416:535-539.
52. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ: Effects of
secreted oligomers of amyloid beta-protein on hippocampal synaptic
plasticity: a potent role for trimers. J Physiol 2006, 572:477-492.
53. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M,
Ashe KH: A specific amyloid-beta protein assembly in the brain impairs
memory. Nature 2006, 440:352-357.
54. Price DL, Tanzi RE, Borchelt DR, Sisodia SS: Alzheimer’s disease: genetic
studies and transgenic models. Annu Rev Genet 1998, 32:461-493.
55. Ashe KH, Zahs KR: Probing the biology of Alzheimer’s disease in mice.
Neuron 2010, 66:631-645.




56. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC,
Wilson RS: Neuropathology of older persons without cognitive
impairment from two community-based studies. Neurology 2006,
66:1837-1844.
57. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P,
Buxbaum JD: Correlation between elevated levels of amyloid beta-
peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
doi:10.1186/alzrt121
Cite this article as: Moore et al.: Overlapping profiles of Ab peptides in
the Alzheimer’s disease and pathological aging brains. Alzheimer’s
Research & Therapy 2012 4
Moore et al. Alzheimer’s Research & Therapy 2012,
